Last reviewed · How we verify
T.Prazosin
T.Prazosin is an alpha-1 adrenergic receptor antagonist.
T.Prazosin is an alpha-1 adrenergic receptor antagonist. Used for Hypertension, Benign prostatic hyperplasia.
At a glance
| Generic name | T.Prazosin |
|---|---|
| Also known as | T.Prazosin (sun pharma) |
| Sponsor | Haffkine Bio-Pharmaceutical Corporation Ltd. |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Alpha-1 adrenergic receptor antagonists block the action of the neurotransmitter norepinephrine at alpha-1 adrenergic receptors, leading to vasodilation and decreased blood pressure. This class of drugs is primarily used to treat hypertension and benign prostatic hyperplasia. T.Prazosin is a selective alpha-1 adrenergic receptor antagonist, which means it has a higher affinity for alpha-1 adrenergic receptors than for other adrenergic receptors.
Approved indications
- Hypertension
- Benign prostatic hyperplasia
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T.Prazosin CI brief — competitive landscape report
- T.Prazosin updates RSS · CI watch RSS
- Haffkine Bio-Pharmaceutical Corporation Ltd. portfolio CI